AngioDynamics Introduces Morpheus™ Peripherally Inserted Central Catheter in the United States Queensbury, NY, April 14, 2004 – ANGIODYNAMICS, INC., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) today announced the introduction of the Morpheus™ peripherally inserted

AngioDynamics Announces Market Launch of SpeedLyser™ Thrombolytic Catheter Queensbury, NY, April 13, 2004 – ANGIODYNAMICS, INC., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) announced today the worldwide market launch of the SpeedLyser™ Thrombolytic catheter—a

Study Concludes Ultrasound
Guided Percutaneous Ablation of Small Invasive Breast Carcinomas is Feasible and
Safe

RITA Medical Systems to Present at Wells Fargo Securities' Health Care Fireside Chat MOUNTAIN VIEW, Calif., March 22 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (Nasdaq: RITA) today announced that it is scheduled to make an investor presentation at Wells Fargo Securities' Health Care

Japan Ministry of Health,
Labor and Welfare Approves Reimbursement of Radiofrequency Ablation Treatment
for Liver Cancer Effective April 1, 2004

AngioDynamics Files Registration Statement for Initial Public Offering Queensbury, NY, March 5, 2004 – AngioDynamics, Inc., a wholly owned subsidiary of E-Z-EM, Inc. (AMEX: EZM) today announced that it has filed a registration statement with the Securities and Exchange Commission for an

2003 Technology
Evaluations and Published Clinical Data Facilitating Reimbursement Reviews By
Insurers Establishing Coverage Guidelines

RITA Medical Systems to Present at Medtech Insight's ``Investment in Innovation'' Conference RITA Medical Systems to Present at Medtech Insight's ``Investment in Innovation'' Conference IRVINE, Calif., Feb 24, 2004 (BUSINESS WIRE) -- RITA Medical Systems (Nasdaq:RITA) will be presenting on February

95% Success Rate in Patients Who Failed Standard Treatments Reported in Multi-Center Trial

Sales of $4.2 Million; Reduced Operating Expenses; Improved Bottom-Line Results

LOUISVILLE, Ky., Feb 10, 2004 (BUSINESS WIRE) -- Norton Cancer Hospital surgeons, Dr. Robert Martin and Dr. Kelly McMasters are pioneering the use of radiofrequency ablation (RFA) to treat cancer of the liver. RFA treatment is far less invasive than traditional open surgery.

AngioDynamics Announces FDA 510k Clearance of SpeedLyser Infusion Catheter QUEENSBURY, N.Y.--(BUSINESS WIRE)--Feb. 6, 2004--AngioDynamics, Inc., a wholly owned subsidiary of E-Z-EM, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for the Company

AngioDynamics Announces Live Broadcast of ELVS Procedure at ISET Meeting AngioDynamics Announces Live Broadcast of ELVS Procedure at ISET Meeting QUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 29, 2004--AngioDynamics, Inc., a wholly-owned subsidiary of E-Z-EM, Inc., today announced that a live

AngioDynamics Announces the Release of New 65cm ELVS Procedure Kit AngioDynamics Announces the Release of New 65cm ELVS Procedure Kit QUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 27, 2004--AngioDynamics, Inc., a wholly-owned subsidiary of E-Z-EM, Inc., today announced the launch of the new ELVS ™

AngioDynamics Comments On Patent Infringement Lawsuit Related To ELVS QUEENSBURY, N.Y., Tuesday, January 23, 2004 – AngioDynamics, Inc. a wholly owned subsidiary of E-Z-EM, Inc. (Amex: EZM) today announced that Diomed, Inc., a subsidiary of Diomed Holdings, Inc., has filed a lawsuit against

New American Medical
Association CPT Code and Medicare National Unadjusted Payment Rates for
Reimbursement Effective Jan. 1, 2004

RITA Medical Systems Announces Fourth Quarter and Year-End Results Release and Conference Call Date MOUNTAIN VIEW, Calif., Jan. 15 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (Nasdaq: RITA) today announced plans to release its financial results for the fourth quarter and fiscal year ended

RITA Medical Systems Names Darrin R. Uecker Chief Technology Officer; Experienced Medical Device Executive to Lead Company's Technology Strategy RITA Medical Systems Names Darrin R. Uecker Chief Technology Officer; Experienced Medical Device Executive to Lead Company's Technology Strategy MOUNTAIN

Six-Month and One-Year Data Reports 90% Success Rate for Minimally
Invasive Radiofrequency Ablation Procedure

Forty-Eight Percent Five-Year Survival Rate for Primary Liver Cancer Patients Treated With Minimally Invasive Procedure Reported at RSNA Annual Meeting